BACKGROUND: Bone metastasis of prostate cancer is associated with pain and reduced overall survival (OS). Radium-223, which is expected to reduce bone pain and prolong OS, was recently approved in Japan. AIM: The aim of this study was to investigate the usefulness of the bone scan index by comparing the outcomes and factors according to response in Japanese patients treated with radium-223. METHODS AND RESULTS: Twenty patients receiving radium-223 were divided into two groups according to whether they did or did not achieve a bone scan index decrease of at least one point (beneficial and non-beneficial groups, respectively). The clinical characteristics at baseline and after three and six treatment cycles were compared using χ2 tests and Student's t-tests or Mann-Whitney U tests, and survival was estimated and compared using the Kaplan-Meier method and log-rank test, respectively. Fourteen (70%) and six patients (30%) were categorized into the beneficial and non-beneficial groups, respectively. Patients in the former group were significantly more likely to have a higher Eastern Cooperative Oncology Group performance status score and receive a greater number of radium-223 injections (P < 0.05). Furthermore, patients in the beneficial group had a significantly longer OS (P < 0.05). Regarding safety, one and three patients in the beneficial and non-beneficial groups, respectively, prematurely discontinued radium-223 because of an increased prostate-specific antigen level, decreased hemoglobin level, or femoral fracture. CONCLUSION: Radium-223 appears generally safe in this population. Patients with good bone scan index response have better performance status, receive more injections of radium-223, and achieve OS prolongation. Bone scan index is a useful biomarker of survival outcomes and can be a valuable assessment tool in patients with metastatic castration-resistant prostate cancer who are treated with radium-223.
BACKGROUND: Bone metastasis of prostate cancer is associated with pain and reduced overall survival (OS). Radium-223, which is expected to reduce bone pain and prolong OS, was recently approved in Japan. AIM: The aim of this study was to investigate the usefulness of the bone scan index by comparing the outcomes and factors according to response in Japanese patients treated with radium-223. METHODS AND RESULTS: Twenty patients receiving radium-223 were divided into two groups according to whether they did or did not achieve a bone scan index decrease of at least one point (beneficial and non-beneficial groups, respectively). The clinical characteristics at baseline and after three and six treatment cycles were compared using χ2 tests and Student's t-tests or Mann-Whitney U tests, and survival was estimated and compared using the Kaplan-Meier method and log-rank test, respectively. Fourteen (70%) and six patients (30%) were categorized into the beneficial and non-beneficial groups, respectively. Patients in the former group were significantly more likely to have a higher Eastern Cooperative Oncology Group performance status score and receive a greater number of radium-223 injections (P < 0.05). Furthermore, patients in the beneficial group had a significantly longer OS (P < 0.05). Regarding safety, one and three patients in the beneficial and non-beneficial groups, respectively, prematurely discontinued radium-223 because of an increased prostate-specific antigen level, decreased hemoglobin level, or femoral fracture. CONCLUSION:Radium-223 appears generally safe in this population. Patients with good bone scan index response have better performance status, receive more injections of radium-223, and achieve OS prolongation. Bone scan index is a useful biomarker of survival outcomes and can be a valuable assessment tool in patients with metastatic castration-resistant prostate cancer who are treated with radium-223.
Authors: David Ulmert; Reza Kaboteh; Josef J Fox; Caroline Savage; Michael J Evans; Hans Lilja; Per-Anders Abrahamsson; Thomas Björk; Axel Gerdtsson; Anders Bjartell; Peter Gjertsson; Peter Höglund; Milan Lomsky; Mattias Ohlsson; Jens Richter; May Sadik; Michael J Morris; Howard I Scher; Karl Sjöstrand; Alice Yu; Madis Suurküla; Lars Edenbrandt; Steven M Larson Journal: Eur Urol Date: 2012-01-27 Impact factor: 20.096
Authors: Howard I Scher; Michael J Morris; Walter M Stadler; Celestia Higano; Ethan Basch; Karim Fizazi; Emmanuel S Antonarakis; Tomasz M Beer; Michael A Carducci; Kim N Chi; Paul G Corn; Johann S de Bono; Robert Dreicer; Daniel J George; Elisabeth I Heath; Maha Hussain; Wm Kevin Kelly; Glenn Liu; Christopher Logothetis; David Nanus; Mark N Stein; Dana E Rathkopf; Susan F Slovin; Charles J Ryan; Oliver Sartor; Eric J Small; Matthew Raymond Smith; Cora N Sternberg; Mary-Ellen Taplin; George Wilding; Peter S Nelson; Lawrence H Schwartz; Susan Halabi; Philip W Kantoff; Andrew J Armstrong Journal: J Clin Oncol Date: 2016-02-22 Impact factor: 44.544
Authors: Nicholas J Vogelzang; Robert E Coleman; Jeff M Michalski; Sten Nilsson; Joe M O'Sullivan; Christopher Parker; Anders Widmark; Marcus Thuresson; Lei Xu; Joseph Germino; Oliver Sartor Journal: Clin Genitourin Cancer Date: 2016-08-08 Impact factor: 2.872
Authors: Sunil Parimi; Erica Tsang; Abraham Alexander; Michael Mckenzie; Francois Bachand; Katherine Sunderland; Kim N Chi; Maria Aparicio; Daniel Worsley; Scott Tyldesley Journal: Can Urol Assoc J Date: 2017-10 Impact factor: 1.862
Authors: Asha Leisser; Marzieh Nejabat; Markus Hartenbach; Reza Agha Mohammadi Sareshgi; Shahrokh Shariat; Gero Kramer; Michael Krainer; Marcus Hacker; Alexander R Haug Journal: Oncotarget Date: 2018-03-05